Trial Profile
A phase II double-blind placebo-controlled randomized study of GDC- 0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase inhibitor therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Apitolisib (Primary) ; Pictrelisib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FERGI
- Sponsors Genentech
- 10 Dec 2022 This trial has been discontinued in UK - MHRA (End Date: 13 May 2015) according to European Clinical Trials Database record.
- 01 Jul 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2016 The trial was completed in Hungary (end date:2016-04-07).